Prognostic Significance of Tumor-infiltrating T-lymphocytes in Primary and Metastatic Lesions of Advanced Stage Ovarian Cancer
Overview
Oncology
Pharmacology
Authors
Affiliations
Purpose: Ovarian cancer patients with intra-tumoral CD3(+) T-lymphocytes in primary tumor tissue have a better prognosis. This study aims to analyze the presence and relative influence of three important T-lymphocyte subsets, tumor-infiltrating CD8(+) cytotoxic T-lymphocytes (CTL), CD45R0(+) memory T-lymphocytes, and FoxP3(+) regulatory T-lymphocytes (Treg), in primary tumor tissue and omental metastases of patients with ovarian cancer.
Experimental Design: The number of CD8(+), CD45R0(+), and FoxP3(+) T-lymphocytes was determined by immunohistochemistry on a tissue micro array containing ovarian tumor tissue and/or omental metastases obtained at primary debulking surgery from 306 FIGO stage I-IV ovarian cancer patients. Immunohistochemistry data were correlated to clinicopathological parameters and survival data.
Results: High number of CD8(+) CTL and a high CD8(+)/FoxP3(+) ratio in ovarian-derived tumor tissue were associated with increased disease-specific survival and proved to be independent prognostic factors in multivariate analyses. In advanced stage patients, the presence of CD8(+) CTL, CD45R0(+) memory T-lymphocytes, FoxP3(+) Treg or a high CD8(+)/FoxP3(+) ratio in ovarian-derived tumor tissue was associated with an increased disease specific survival in univariate analysis, as was the presence of CD45R0(+) memory T-lymphocytes and FoxP3(+) Treg in omental metastases. Furthermore, in advanced stage patients CD8(+) cytotoxic and FoxP3(+) regulatory T-lymphocytes infiltrating ovarian-derived tumor tissue were independent predictors of increased prognosis.
Conclusions: T-lymphocytes infiltrating primary and metastatic ovarian cancer sites are associated with improved prognosis. These associations are especially distinct in advanced stage patients, underlining the potential for immunotherapy as a broadly applicable therapeutic strategy.
Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer.
Connor A, Lyons P, Kilgallon A, Simpson J, Perry A, Lysaght J Heliyon. 2024; 10(20):e38888.
PMID: 39640610 PMC: 11620064. DOI: 10.1016/j.heliyon.2024.e38888.
Huo M, Adeerjiang Y, Abulitipu A, Khan U, Li X, Zhang L Front Oncol. 2024; 14:1325575.
PMID: 39534095 PMC: 11554530. DOI: 10.3389/fonc.2024.1325575.
Guo H, Zhang L, Su H, Yang J, Lei J, Li X Heliyon. 2024; 10(18):e38014.
PMID: 39347397 PMC: 11437944. DOI: 10.1016/j.heliyon.2024.e38014.
Cunha D, Neves M, Silva D, Silvestre A, Nunes P, Arrobas F Cells. 2024; 13(11.
PMID: 38891095 PMC: 11172364. DOI: 10.3390/cells13110964.
Chang S, Ke T, Chen W, Shyu W, Jeng L Front Immunol. 2024; 15:1329615.
PMID: 38476223 PMC: 10927724. DOI: 10.3389/fimmu.2024.1329615.